SCHEMBL18535153

SCHEMBL18535153

CC(C)(C)OC(=O)N1CC(O)(C#N)C1

nearest known ligand 0.43

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
USP2 O75604 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
CTSK P43235 1/20 0.42
MEN1 O00255 1/20 0.40
ALDH1A1 P00352 1/20 0.40
MAPT P10636 1/20 0.40
KMT2A Q03164 1/20 0.40
GPR119 Q8TDV5 4/20 0.39
NR1H2 P55055 2/20 0.38
HPGD P15428 1/20 0.37
EPHX2 P34913 1/20 0.37
RECQL P46063 1/20 0.36
EPHX1 P07099 1/20 0.36
JAK2 O60674 1/20 0.35
JAK1 P23458 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13993957 0.87 USP2 (0.42) USP2SMN1; SMN2CTSKMEN1ALDH1A1
SCHEMBL10163302 0.84 MEN1 (0.44) USP2SMN1; SMN2CTSKMEN1ALDH1A1
SCHEMBL1973674 0.83 USP2 (0.49) USP2SMN1; SMN2CTSKMEN1ALDH1A1
SCHEMBL28956005 0.82 USP2 (0.43) USP2SMN1; SMN2CTSKMEN1ALDH1A1
SCHEMBL1706650 0.82 USP2 (0.43) USP2SMN1; SMN2CTSKMEN1ALDH1A1
SCHEMBL992628 0.82 USP2 (0.43) USP2SMN1; SMN2CTSKMEN1ALDH1A1
SCHEMBL25303284 0.81 MEN1 (0.43) USP2SMN1; SMN2CTSKMEN1ALDH1A1
SCHEMBL851117 0.81 USP2 (0.42) USP2SMN1; SMN2CTSKMEN1ALDH1A1
SCHEMBL18588192 0.79 USP2 (0.41) USP2SMN1; SMN2CTSKMEN1ALDH1A1
SCHEMBL13957351 0.79 USP2 (0.41) USP2SMN1; SMN2CTSKMEN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117003681-A Inhibitor intermediate and synthesis method thereof 苏州汉德创宏生化科技有限公司 2023-11-07 CN claimed
US-20250129021-A1 SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS Interdict Bio, Inc. (US) 2025-04-24 US disclosed
WO-2025064718-A1 SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS Interdict Bio, Inc. (US) 2025-03-27 WO disclosed
EP-4126855-B1 COMPOUNDS AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTIONS HOFFMANN LA ROCHE (CH) 2024-04-24 EP disclosed
WO-2024049976-A1 N-METHYL-4-(QUINOLIN-2-YL)PYRIDIN-2-AMINE COMPOUNDS ABBVIE INC. (US) 2024-03-07 WO disclosed
US-20230365558-A1 TETRAHYDROISOQUINOLINE DERIVATIVE AND USE THEREOF MEDSHINE DISCOVERY INC. (CN) 2023-11-16 US disclosed
US-20230365558-A1 TETRAHYDROISOQUINOLINE DERIVATIVE AND USE THEREOF MEDSHINE DISCOVERY INC. (CN) 2023-11-16 US disclosed
CN-117003681-A Inhibitor intermediate and synthesis method thereof 苏州汉德创宏生化科技有限公司 2023-11-07 CN disclosed
CN-117003681-A Inhibitor intermediate and synthesis method thereof 苏州汉德创宏生化科技有限公司 2023-11-07 CN disclosed
EP-4219461-A1 TETRAHYDROISOQUINOLINE DERIVATIVE AND USE THEREOF Medshine Discovery Inc. (CN) 2023-08-02 EP disclosed
US-20230167127-A1 COMPOUNDS AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTION HOFFMANN-LA ROCHE INC. (US) 2023-06-01 US disclosed
WO-2023016527-A1 CLASS OF BENZOXAZINE SPIRO COMPOUNDS AND PREPARATION METHOD THEREFOR 南京明德新药研发有限公司 2023-02-16 WO disclosed
EP-4126855-A1 COMPOUNDS AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTION F. Hoffmann-La Roche AG (CH) 2023-02-08 EP disclosed
CN-115298176-A Compounds and their use in the treatment of bacterial infections 豪夫迈·罗氏有限公司 2022-11-04 CN disclosed
WO-2022063094-A1 TETRAHYDROISOQUINOLINE DERIVATIVE AND USE THEREOF 南京明德新药研发有限公司 2022-03-31 WO disclosed
WO-2021190727-A1 COMPOUNDS AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTION F. HOFFMANN-LA ROCHE AG (CH) 2021-09-30 WO disclosed
EP-2763990-B1 PYRROLOPYRAZINE KINASE INHIBITORS HOFFMANN LA ROCHE (CH) 2017-02-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250129021-A1 SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS MYC, KRAS, NRAS USP2 1781/4885SMN1; SMN2 1576/4885CTSK 2693/4885
US-20230365558-A1 TETRAHYDROISOQUINOLINE DERIVATIVE AND USE THEREOF CYP3A7, UGT2B7, SFPQ USP2 4653/4885SMN1; SMN2 4600/4885CTSK 2324/4885
US-20230167127-A1 COMPOUNDS AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTION LTB4R, C5, C3AR1 USP2 3512/4885SMN1; SMN2 4067/4885CTSK 1862/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.